A systematic review of catechol-o-methyltransferase inhibitors: Efficacy and safety in clinical practice

Clinical Neuropharmacology

Volumn 35, Issue 4, 2012, Pages 185-190

  Marsala, Sandro Zambito ^a   Gioulis, Manuela ^a   Ceravolo, Roberto ^b   Tinazzi, Michele ^c  

^a SAN MARTINO HOSPITAL   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

Author keywords

catechol O methyltransferase inhibitors; entacapone; levodopa; tolcapone

Indexed keywords

CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; ENTACAPONE; LEVODOPA; NEBICAPONE; PLACEBO; RASAGILINE; TOLCAPONE;

ADJUVANT THERAPY; CLINICAL PRACTICE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; LIVER TOXICITY; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS (TOPIC); MORNING DOSAGE; MOTOR PERFORMANCE; MULTICENTER STUDY (TOPIC); OPEN STUDY; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; TREATMENT RESPONSE; UNIFIED PARKINSON DISEASE RATING SCALE;

ACETOPHENONES; ANTIPARKINSON AGENTS; BENZOPHENONES; CATECHOL O-METHYLTRANSFERASE; CATECHOLS; CLINICAL TRIALS AS TOPIC; DRUG-INDUCED LIVER INJURY; ENZYME INHIBITORS; HUMANS; NITRILES; NITROPHENOLS; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 84863911386     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0b013e31825c034a     Document Type: Review

References (51)

1. Kaakkola S, Teravainen H, Ahtila S, et al. Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology 1994;44(1):77-80. (Pubitemid 24029433)
2. Schrag A. Entacapone in the treatment of Parkinson's disease. Lancet Neurol 2005;4(6):366-370. (Pubitemid 40720033)
3. Kaakkola S. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs 2000;59(6):1233-1250. (Pubitemid 30410142)
4. Ferreira JJ, Almeida L, Cunha L, et al. Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease. Clin Neuropharmacol 2008;31(1):2-18. (Pubitemid 351321436)
5. Ferreira JJ, Rascol O, Poewe W, et al. A double-blind, randomized, placebo and active-controlled study of nebicapone for the treatment of motor fluctuations in Parkinson's disease. CNS Neurosci Ther 2010;16(6):337-347.
6. 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. 2002;43(3):201-207.
7. Nutt JG, Woodward WR, Beckner RM. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994;44(5):913-919. (Pubitemid 24158809)
8. Hauser RA, Poewe W, LeWitt P, et al. Levodopa/carbidopa/entacapone (Stalevo). Neurology 2004;62(1 suppl 1):S64-S71. (Pubitemid 38082854)
9. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. PLoS Med 2009;6(7):e1000100.
10. Merello M, Lees AJ, Webster R, et al. Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57(2): 186-189. (Pubitemid 24050458)
11. Bet L, Bareggi SR, Pacei F, et al. Bimodal administration of entacapone in Parkinson's disease patients improves motor control. Eur J Neurol 2008;15(3):268-273. (Pubitemid 351257918)
12. Durif F, Devaux I, Pere J, et al. Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study. Eur Neurol 2001;45(2):111-118. (Pubitemid 32215799)
13. Muller T, Erdmann C, Muhlack S, et al. Entacapone improves complex movement performance in patients with Parkinson's disease. J Clin Neurosci 2007;14(5):424-428. (Pubitemid 46453184)
14. Roberts JW, Cora-Locatelli G, Bravi D, et al. Catechol-O- methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology 1993;43(12 I): 2685-2688. (Pubitemid 24004569)
15. Yamamoto M, Yokochi M, Kuno S. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease. J Neural Transm 1997;104(2-3):229-236. (Pubitemid 27196477)
16. Kupsch A, Trottenberg T, Bremen D. Levodopa therapy with entacapone in daily clinical practice: results of a post-marketing surveillance study. Curr Med Res Opin 2004;20(1):115-120. (Pubitemid 38063463)
17. Grandas F, Hernandez B. Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson's disease patients: the effects of an early therapeutic intervention. Eur J Neurol 2007;14(3):282-289. (Pubitemid 46384864)
18. Paci C, Sanguigni S, Carboni T, et al. The use of entacapone in patients with advanced Parkinson's disease: 2 years' experience. Neurol Sci 2003;24(3):197-198. (Pubitemid 37304311)
19. Parashos SA, Wielinski CL, Kern JA. Frequency, reasons, and risk factors of entacapone discontinuation in Parkinson disease. Clin Neuropharmacol 2004;27(3):119-123. (Pubitemid 38746011)
20. Damier P, Viallet F, Ziegler M, et al. Levodopa/DDCI and entacapone is the preferred treatment for Parkinson's disease patients with motor fluctuations in routine practice: a retrospective, observational analysis of a large French cohort. Eur J Neurol 2008;15(7):643-648. (Pubitemid 351814412)
21. Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 2010;68(1):18-27.
22. Larsen JP, Worm-Petersen J, Siden A, et al. The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease. Eur J Neurol 2003;10(2):137-146. (Pubitemid 36308207)
23. Destee A, Rerat K, Bourdeix I. Is there a difference between levodopa/dopa-decarboxylase inhibitor and entacapone and levodopa/dopa- decarboxylase inhibitor dose fractionation strategies in Parkinson's disease patients experiencing symptom re-emergence due to wearing-off? The honeymoon study. Eur Neurol 2009;61(2):69-75.
24. Rinne UK, Larsen JP, Siden A. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology 1998;51(5):1309-1314. (Pubitemid 28520549)
25. Poewe WH, Deuschl G, Gordin A. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 2002;105(4):245-255. (Pubitemid 34407226)
26. Brooks DJ, Leinonen M, Kuoppamaki M. Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson's disease. J Neural Transm 2008;115(6):843-849.
27. Hauser RA, Panisset M, Abbruzzese G. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. Mov Disord 2009;24(4):541-550.
28. Nissinen H, Kuoppamaki M, Leinonen M. Early versus delayed initiation of entacapone in levodopa-treated patients with Parkinson's disease: a long-term, retrospective analysis. Eur J Neurol 2009;16(12):1305-1311.
29. Linazasoro G, Kulisevsky J, Hernandez B. Should levodopa dose be reduced when switched to Stalevo? Eur J Neurol 2008;15(3):257-261. (Pubitemid 351257922)
30. Lees AJ, Ratziu V, Tolosa E, et al. Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease. J Neurol Neurosurg Psychiatry 2007;78(9):944-948. (Pubitemid 47310829)
31. Rajput AH, Martin W, Saint-Hilaire MH, et al. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 1997;49(4):1066-1071.
32. Adler CH, Singer C, O'Brien C, et al. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III. Arch Neurol 1998;55(8):1089-1095. (Pubitemid 28367234)
33. Stocchi F, De Pandis MF. Utility of tolcapone in fluctuating Parkinson's disease. Clin Interv Aging 2006;1(4):317-325.
34. Reichmann H, Boas J, MacMahon D, et al. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations. Acta Neurol Scand 2005;111(1):21-28.
35. Fung VS, Herawati L, Wan Y, et al. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone. Mov Disord 2009;24(1):25-31.
36. Onofrj M, Thomas A, Vingerhoets F, et al. Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: results of a large multicentre open-label study. J Neural Transm 2004;111(8):1053-1063. (Pubitemid 39037126)
37. Olanow CW, Kieburtz K, Stern M, et al. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch Neurol 2004;61(10):1563-1568. (Pubitemid 39350267)
38. Kinnunen E, Myllyla V, Agid Y, et al. Entacapone to tolcapone switch: multicenter double-blind, randomized, active-controlled trial in advanced Parkinson's disease. Mov Disord 2007;22(1):14-19. (Pubitemid 46382668)
39. Onofrj M, Thomas A, Iacono D, et al. Switch-over from tolcapone to entacapone in severe Parkinson's disease patients. Eur Neurol 2001;46(1):11-16. (Pubitemid 32656669)
40. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005;365(9463):947-954. (Pubitemid 41071428)
41. Kaakkola S. Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease. Int Rev Neurobiol 2010;95:207-225.
42. Gershanik O, Emre M, Bernhard G, et al. Efficacy and safety of levodopa with entacapone in Parkinson's disease patients suboptimally controlled with levodopa alone, in daily clinical practice: an international, multicentre, open-label study. Prog Neuropsychopharmacol Biol Psychiatry 2003;27(6):963-971. (Pubitemid 37141384)
43. Koller W, Guarnieri M, Hubble J, et al. An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off. J Neural Transm 2005;112(2):221-230. (Pubitemid 40179116)
44. Kuoppamaki M, Korpela K, Marttila R, et al. Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily. Eur J Clin Pharmacol 2009;65(5):443-455.
45. Jog M, Panisset M, Suchowersky O, et al. Naturalistic evaluation of entacapone in patients with signs and symptoms of L-dopa wearing-off. Curr Med Res Opin 2008;24(11):3207-3215.
46. Stowe R, Ives N, Clarke CE, et al. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications. Cochrane Database Syst Rev 2010;(7):CD007166.
47. Gordin A, Kaakkola S, Teravainen H. Clinical advantages of COMT inhibition with entacaponeVa review. J Neural Transm 2004;111(10-11):1343-1363. (Pubitemid 39468395)
48. Ruottinen HM, Rinne UK. Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. Clin Neuropharmacol 1996a;19(3): 222-233.
49. Ruottinen HM, Rinne UK. Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psychiatry 1996b;60(1):36-40. (Pubitemid 26012264)
50. Almeida L, Soares-Da-Silva P. Pharmacokinetics and pharmacodynamics of BIA 3-202, a novel COMT inhibitor, during first administration to humans. Drugs R&D 2003;4(4):207-217. (Pubitemid 36949654)
51. Deane KH, Spieker S, Clarke CE. Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev 2004;(4):CD004553.